-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES IGALMI® AS FIRST AT-HOME ACUTE TREATMENT FOR AGITATION ASSOCIATED WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, OR BIPOLAR I OR II DISORDER IN ADULTS

Reuters·11/16/2026 13:00:05

Please log in to view news